Utilisation pattern of fentanyl transdermal system in The Netherlands

Pharmacoepidemiology and Drug Safety

Volumn 14, Issue 2, 2005, Pages 129-134

  Breekveldt Postma, N S ^a   Penning van Beest, F J A ^a   Herings, R M C ^a,b  

^a PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Prescription database; TTS fentanyl; Utilisation pattern

Indexed keywords

FENTANYL; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PAIN; CHILD; CLINICAL PRACTICE; COHORT ANALYSIS; DOSE RESPONSE; DRUG MEGADOSE; DRUG UTILIZATION; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; INFANT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DRUG UTILIZATION; FEMALE; FENTANYL; HUMANS; INFANT; MALE; MIDDLE AGED; NETHERLANDS; PAIN; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES;

EID: 13844272262     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.1008     Document Type: Article

References (24)

1. Zagari MJ, Mazonson PD, Longton WC. Pharmacoeconomics of chronic non-malignant pain. PharmacoEconomics 1996; 10: 356-377.
2. Portenoy RK. Opioid therapy for chronic non-malignant pain: a review of critical issues. J Pain Symptom Manage 1996; 11: 203-217.
3. WHO. Cancer Pain Relief. WHO: Geneva, 1996.
4. Allan L, Hays H, Jensen NE, et al. Randomised cross-over trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br Med J 2001; 322(7295): 1154-1158.
5. Southam MA. Transdermal fentanyl therapy: system design, pharmacokinetics and efficacy. Anticancer Drugs 1995; 6 Suppl. 3): 29-34.
6. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet 2000; 38(1): 59-89.
7. Dellemijn PL, van Duijn H, Vanneste JA. Prolonged treatment with transdermal fentanyl in neuropathic pain. J Pain Symptom Manage 1998; 16(4): 220-229.
8. Payne R, Chandler S, Einhaus M. Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 1995; 6(Suppl. 3): 50-53.
9. Dellemijn PL. Opioids in non-cancer pain: a life-time sentence? Eur J Pain 2001; 5(3): 333-339.
10. Muijsers RB, Wagstaff AJ. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 2001; 61(15): 2289-2307.
11. Mystakidou K, Befon S, Tsilika E, Dardoufas K, Georgaki S, Vlahos L. Use of TTS fentanyl as a single opioid for cancer pain relief: a safety and efficacy clinical trial in patients naive to mild or strong opioids. Oncology 2002; 62(1): 9-16.
12. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997; 13: 254-261.
13. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: astisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16 1588-1593.
14. Joranson DE, Ryan KM, Gilson AM, Dahl JL. Trends in medical use and abuse of opioids. JAMA 2000; 283(13): 1710-1714.
15. Bell JR. Australian trends in opioid prescribing for chronic non-cancer pain 1986-1996. Med J Aust 1997; 167(1): 26-29.
16. Malkin JD, Ackerman SJ, Schein J, Locklear J, Ashburn M. Cost and utilization patterns of fentanyl transdermal system and oxycodone hydrochloride controlled-release in a California medicaid population. J Managed Care Pharmacy 2002; 8(2): 132-140.
17. Radbruch L, Sabatowski R, Petzke F, Brunsch-Radbruch A, Grond S, Lehmann KA. Transdermal fentanyl for the management of cancer pain: a survey of 1005 patients. Palliat Med 2001; 15(4): 309-321.
18. Herings RMC. PHARMO: a Record Linkage System for Postmarketing Surveillance of Prescription Drugs in The Netherlands [PhD]. Utrecht: Utrecht University; 1993.
19. Donner B, Zenz M, Strumpf M, Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 1998; 15: 168-175.
20. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain Med 1996; 64: 527-534.
21. Sloan R, Moulin DE, Hays H. A clinical evaluation of transdermal therapeutic system fentanyl for the treatment of cancer pain. J Pain Symptom Manage 1998; 16: 102-111.
22. Korte W, de Stoutz N, Morant R. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 1996; 11(3): 139-146.
23. Otis JAD. Clinical review: treatment options for the elderly with severe pain. Consult Pharm 1999; 14(Suppl. A): 19-26.
24. Menten J, Desmedt M, Lossignol D, Mullie A. Longitudinal follow-up of TTS-fentanyl use in patients with cancer-related pain: results of a compassionate-use study with special focus on elderly patients. Curr Med Res Opin 2002; 18(8): 488-498.